 There are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma PDAC. The purpose of this study is to determine the effectiveness and safety of the drugs capecitabine and oxaliplatin in patients who have been diagnosed with advanced and metastatic PDAC treated in the first and second lines. 